JWH-122 is a synthetic cannabimimetic that was discovered by
John W. Huffman
John William Huffman (1932–2022) was a professor of organic chemistry at Clemson University who first synthesised novel cannabinoids. His research, funded by the National Institute on Drug Abuse, was focused on making a drug to target endocanna ...
. It is a methylated analogue of
JWH-018
JWH-018 (1-pentyl-3-(1-naphthoyl)indole, NA-PIMO or AM-678) is an analgesic chemical from the naphthoylindole family that acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. It produces effects in ...
. It has a
Ki of 0.69 nM at CB
1 and 1.2 nM at CB
2.
In January 2015, over 40 people were reportedly sickened after eating a holiday bread called
Rosca de reyes purchased at a bakery in Santa Ana, CA that was laced with JWH-122.
Legal status
Australia
JWH-122 is considered a Schedule 9 prohibited substance in Australia under the
Poisons Standard (October 2015).
A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
China
As of October 2015 JWH-122 is a controlled substance in China.
United States
In the United States, JWH-122 is a
Schedule I Controlled Substance.
See also
*
JWH-193
JWH-193 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB1 r ...
*
JWH-210
*
JWH-398
JWH-398 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It has mild selectivity for CB1 with a Ki of 2.3 nM and 2.8 nM at CB2. This synthetic chemical comp ...
*
List of JWH cannabinoids
References
{{Cannabinoids
JWH cannabinoids
Naphthoylindoles
Designer drugs
CB1 receptor agonists
CB2 receptor agonists